Recruiting
Phase 2

Stereotactic Body Radiation Therapy

Sponsor:

Jonsson Comprehensive Cancer Center

Code:

NCT06436612

Conditions

Abdominopelvic Sarcomas

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy

Study Details

Brief summary:

Recent advances in radiation treatment have allowed for higher doses per treatment to be delivered safely. This study plans to use an MRI-guided linear accelerator to deliver the radiation treatment to ensure that the radiation dose is administered to the cancerous tumor, not the vital body organs.

Potential participants with a sarcoma diagnosis will be referred to Radiation Oncology during this study. If the participant is interested in participating in this study, s/he receives radiation treatment daily for 5 consecutive days except for weekends and holidays. Within 12 weeks of completing the radiation therapy, the participant will have the primary tumor surgically removed. The radiation oncology team will follow the patients for 5 years after completing radiation therapy.

Conditions

Abdominopelvic Sarcomas

Study ID

NCT06436612

Start date

May 30, 2024

Status verified date

Jun, 2026

Completion date

May 26, 2028

Anticipated

Primary completion date

May 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Histologically confirmed sarcoma
  • Primary or recurrent disease involving the abdomen or pelvis
  • Resectable primary lesion
  • Age ≥ 12 years old
  • Karnofsky performance status (KPS) ≥ 70 or Eastern Cooperative Oncology Group (ECOG) 0-2
  • If a woman is of childbearing potential, a negative serum or urine pregnancy test must be documented

Exclusion Criteria:

  • Active treatment of a separate malignancy
  • History of prior irradiation to the area targeted for treatment

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Arm I

MRI or CT-guided SBRT will be delivered in the pre-operative setting. Patients will receive 5.0-6.0 Gy x 5 fractions delivered daily.

Interventions

Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy

stereotactic body radiation therapy (SBRT) administered over 5 days x 5.0 - 6.0 Gy for patients with abdominopelvic sarcomas.

Primary outcome measure

  • Radiation morbidity at 2 years [ Time Frame: At 2 years ]

Central Contacts and Locations

Central contacts

Christy Palodichuk

3107942971cpalodichuk@mednet.ucla.edu

Vincent Basehart

3102678954vbasehart@mednet.ucla.edu

Locations

UCLA / Jonsson Comprehensive Cancer Center

Recruiting

Los Angeles, California, United States, 90095

Contacts

Vincent Basehart

3102678954vbasehart@mednet.ucla.edu

Christine Palodichuk

3107942971cpalodichuk@mednet.ucla.edu

Principal Investigator:

Vishruth Reddy, MD

More Information

Sponsor

Jonsson Comprehensive Cancer Center

Last update posted

Jun 5, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center on 2026-06-05.